Skip to main content
. 2019 Apr;67(4):464–471. doi: 10.4103/ijo.IJO_1244_17

Table 6.

Group survivals

AZT DOXY
1st follow-up (no treat./tot) 43/52 14/51
Switched patients 9 37
2nd follow-up (no treat./tot) 57/80 9/23
Retreated patients 23 14
3rd follow-up (no treat./tot) 77/80 8/23
No improvement 3 15

The table shows group survival rate for each group since the beginning of the study, considering the actual number of patients at any follow-up, and how many of any group were stable or were switched to any other one AZT: Azythromicin; DOXY: Doxycycline